News & Videos - APPILI THERAPEUTICS APLIF

You are currently viewing all stock exchange news of the financial instrument APPILI THERAPEUTICS APLIF regarding all markets in all languages.

> News GlobeNewsWire published a news.

Appili Therapeutics Announces Additional Bridge Loan from Bloom Burton & Co. • • GlobeNewsWire • Stocks

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, April 26, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000 (the “ Bridge Loan ”) from Bloom Burton & Co. Inc....

Thank you Chart

> News GlobeNewsWire published a news.

Appili Therapeutics Signs Definitive Agreement to be Acquired by Aditxt, Inc. • • GlobeNewsWire • Stocks

Transaction consideration provides a significant premium to the Appili shareholders Combined enterprise expected to provide enhanced synergies and resources to advance key programs NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, April 02, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (“ Appili ”), a biopharmaceutical company focused on drug development for infectious diseases and medical...

Thank you Chart

> News GlobeNewsWire published a news.

Researchers Publish Manuscript on the Prevention and Emergency Response to Tularemia Outbreaks • • GlobeNewsWire • Stocks

HALIFAX, Nova Scotia, March 12, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced a publication in the journal Frontiers in Bacteriology on the prevention of tularemia. Appili’s Director of Non-Clinical Research, Dr. Carl Gelhaus, Ph.D., together with medical doctors from the United States Uniformed Services...

Thank you Chart

> News GlobeNewsWire published a news.

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024 • • GlobeNewsWire • Stocks

FDA approved LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL Additional USAFA funding commitment from the U.S. Air Force Academy, intended to advance the ATI-1701 program toward an IND submission to the FDA Engaging regulatory authorities to align on ATI-1801 development plans HALIFAX, Nova Scotia, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for...

Thank you Chart

> News Business Wire published a news.

Appili Therapeutics Joins Dr. Reddy’s, Global Response Aid, and FUJIFILM in Advancing Avigan® Tablets for the Potential Treatment of COVID-19 • • Business Wire • Stocks

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, today announced that it has signed a collaboration, development and supply agreement with Dr. Reddy’s Laboratories Ltd. (BSE:500124, NSE:DRREDDY, NYSE:RDY, “Dr. Reddy’s”) and Global Response Aid (“GRA”). This agreement follows on and is harmonized with the previously announced global licensing transaction (excluding Japan,...

Thank you Chart